Closing the Oval Door.

[1]  S. Bertog,et al.  Percutaneous Left Atrial Appendage Closure With the Watchman Device: Long-Term Results Up to 5 Years. , 2015, JACC. Cardiovascular interventions.

[2]  Saibal Kar,et al.  Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[3]  M. Price,et al.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.

[4]  A. Camm,et al.  Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  D. Singer,et al.  Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. , 2014, American heart journal.

[6]  Petr Neuzil,et al.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.

[7]  Stroke-related costs to double by 2030. , 2013, Managed care.

[8]  D. Lake,et al.  Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. , 2012, The American journal of medicine.

[9]  A. Rabinstein.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2010 .

[10]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[11]  B. Hayes,et al.  Polypharmacy and the geriatric patient. , 2007, Clinics in geriatric medicine.

[12]  A. Waldo.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future PrevalenceMiyasaka Y, Barnes ME, Gersh BJ, et al (Mayo Clinic, Rochester, Minn): Circulation 114:119–125, 2006§ , 2007 .

[13]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[14]  A. Go.  The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. , 2005, The American journal of geriatric cardiology.

[15]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.